FDA Seeks Feedback on Voluntary Device Improvement Program
Published Date: 7/17/2026
Notice
Summary
The FDA wants your thoughts on a new plan to collect info from medical device makers who join a Voluntary Improvement Program. This program aims to help companies improve their devices without extra paperwork stress. If you’re involved in making or managing medical devices, you’ve got until September 15, 2026, to share your feedback—no fees, just your voice!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Estimated annual reporting burden
FDA estimates the VIP information collection will produce a total annual burden of 6,056 hours across listed activities: site manufacturer applications — 300 responses at 0.08 hours each (24 hours); aggregate data reporting — 4 responses at 8 hours each (32 hours); and summaries of site appraisals — 300 responses at 20 hours each (6,000 hours).
Estimated burden reduced from prior estimate
FDA states its estimated burden for this collection reflects a decrease of 2,009 hours and a decrease of 200 responses compared to its prior estimate, an adjustment attributed to device registration/listing data and informal stakeholder feedback.
Who may join the Voluntary Program
If you make medical devices, only eligible manufacturers whose marketing applications are reviewed under the Federal Food, Drug, and Cosmetic Act sections 510(k), 513, 515, or 520 may participate in the FDA's Voluntary Improvement Program (VIP). The VIP participation rules and eligibility are described in the FDA guidance titled "Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program."
Third‑party appraisals sent to FDA
As part of the VIP, third‑party appraisers evaluate participating manufacturers and the FDA will receive information about participating manufacturers' capability and performance from those appraisals. The VIP is facilitated by the Medical Device Innovation Consortium (MDIC).
Public comment opportunity and deadline
If you are involved in making or managing medical devices, you may submit comments on the proposed information collection by September 15, 2026, via https://www.regulations.gov or by mail to FDA's Dockets Management Staff. The notice explains how to submit confidential versus public comments.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
2026-17598, Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the generic collection of focus group information as used by FDA for all FDA-regulated products.
Previous / Next Documents
Previous: 2026-14435, Agency Information Collection Activities; Proposed Collection; Comment Request; Voluntary National Retail Food Regulatory Program Standards
The FDA wants your thoughts on how they collect info about food safety programs that stores can join voluntarily. This affects food regulators and businesses aiming to keep food safe and could shape how info is gathered without adding extra costs. You’ve got until September 15, 2026, to share your feedback and help make food safety smoother and smarter!
Next: 2026-14437, Proposed Collection; Comment Request
The Railroad Retirement Board wants your thoughts on updates to a form used when someone quits their job and applies for unemployment benefits. They’ve made some wording clearer and added a question about efforts to fix problems before leaving work. If you’re affected, these changes might save you time and help the agency get better info—comments are open now, so don’t miss your chance to weigh in!